
Keywords: آنالوگهای انسولین; EMA; European Medicines Agency; FDA; The Food and Drug Administration; NPH; neutral protamine hagedorn; PROBE; prospective, randomised, open, blinded endpoint; Type 1 diabetes; Severe hypoglycemia; HbA1c; Human insulin; Insulin analogs; Personalized thera